@article{ATM10630,
author = {Marco Zuin and Claudio Picariello and Lina Marcantoni and Loris Roncon},
title = {Burden of costs associated with heparin-induced thrombocytopenia: is time to remove unfractionated heparin from the drug formularies in medical institutions?},
journal = {Annals of Translational Medicine},
volume = {4},
number = {12},
year = {2016},
keywords = {},
abstract = {Heparin-induced thrombocytopenia (HIT) represents a serious complication of heparin therapy. Despite generally safe, heparin use can trigger a transient and life-threatening immune-mediated response in which immunoglobulin G antibodies set off immunological complexes against platelet factor 4 (PF4) (1). This determines a highly pro-thrombotic state through different pathways: intensive platelet aggregation, augmented thrombin generation and intravascular platelet aggregation.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/10630}
}